Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessAdient Shares Up 4 percent Following Q3 EPS Beat

Adient Shares Up 4 percent Following Q3 EPS Beat

Add to Favorite
Added to Favorite


Adient (NYSE:ADNT) shares rose more than 4% on Monday following the company’s reported Q3 results, with EPS of $0.08 coming in better than the Street estimate of ($0.04).
According to the analysts at Deutsche Bank, the company’s latest guidance trim should help de-risk the 2022 outlook, and enable investors to focus on 2023 when industry volume recovery could contribute to significant EBITDA growth.
The analysts now forecast 2022 sales of $14.0 billion (down from $14.1 billion) and EBITDA of $647 million (down from $681 million), in line with management’s latest guidance range.
Looking ahead, the analysts still believe the company could recover a significant portion of the $600 million in cost inefficiencies it has identified, as industry volumes rebound and production schedules stabilize, although this could be partly offset by headwinds from FX and rising energy costs, particularly in Europe. Accordingly, the analysts reduced their 2023 sales/EBITDA estimates to $15.5 billion/$964 million (6.2% margin), from $15.8 billion/$1.002 billion (6.4% margin) previously, still representing considerable growth from 2022.
The analysts believe the company is very well positioned to benefit from industry volume rebound, reduced inefficiencies from higher capacity utilization, and its relatively successful recovery of commodities headwinds, but it certainly remains exposed to some persistent industry and macro headwinds.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Advance Auto Parts Downgraded to Sell Amid Earnings Miss and Weak Outlook

CFRA analysts downgraded Advance Auto Parts (NYSE:AAP) from Hold...

Guggenheim Reiterates Buy Rating on Cabaletta Bio Amid Promising Data

Guggenheim analysts reaffirmed a Buy rating and a $23...

Goldman Sachs Initiates Neutral Coverage on Doximity, Highlights Balanced Growth Potential

Goldman Sachs analysts initiated coverage on Doximity (NYSE:DOCS) with...

JPMorgan Downgrades bluebird bio to Underweight Following Q3 Results

JPMorgan analysts downgraded bluebird bio (NASDAQ:BLUE) from Neutral to...